Revealing the genomic heterogeneity of melanoma  by Kabbarah, Omar & Chin, Lynda
	 p r e v i e w s
2554–2559.
Woodgett, J.R. (2005). Curr. Opin. Cell Biol. 17, 
150–157.
Yoeli-Lerner, M., Yiu, G.K., Rabinovitz, I., Erhardt, 
P., Jauliac, S., and Toker, A. (2005). Mol. Cell 20, 
539–550.
Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and 
Hung, M.C. (2001). Nat. Cell Biol. 3, 973–982. 
Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., 
Gunduz, M., and Hung, M.C. (2004). Nat. Cell 
Biol. 6, 931–940.
DOI: 10.1016/j.ccr.2005.11.006Revealing the genomic heterogeneity of melanoma
The melanoma genome possesses numerous recurrent chromosomal rearrangements, and embedded within this complex-
ity are clues critical to disease pathogenesis and response to therapy. High-resolution genome-wide DNA copy number 
approaches, in conjunction with gene-specific mutational analyses, appear poised to define keystone molecular events, 
provide more accurate classification schemes, and set the stage for the design of rational therapies that may finally have an 
impact on survival of this deadly disease.The rapid rise in melanoma incidence 
and the high lethality associated with 
advanced disease (reviewed in Thompson 
et al., 2005) has motivated efforts to 
define the genetic and environmental 
factors driving melanoma genesis and 
progression. It is generally accepted that 
melanoma risk is modulated by skin pig-
mentation patterns, such as those linked 
to MC1R polymorphisms (Palmer et al., 
2000), and early exposure to ultravio-
let (UV) light (reviewed in Thompson et 
al., 2005). Stereotypical genetic lesions 
in melanoma include disruption of the 
CDKN2A familial melanoma locus that 
encodes for INK4A and ARF; activation of 
MAPK pathway components, commonly 
at the levels of BRAF and NRAS; and acti-
vation of the PI3K-AKT pathway through 
loss of PTEN (reviewed in Chudnovsky 
et al., 2005; Gray-Schopfer et al., 2005). 
Beyond these well-known and validated 
genetic events, genome-wide high-reso-
lution technologies have been used 
to scan the highly complex melanoma 
genome, revealing the existence of addi-
tional genetic elements governing disease 
genesis and progression (Garraway et al., 
2005; Curtin et al., 2005; O.K. and L.C., 
unpublished data). These data show that 
the life history of melanoma is shaped by 
extensive chromosomal rearrangements, 
particularly recurrent chromosomal gains/
amplifications and losses/deletions. That 
these copy number alterations carry 
pathogenetic significance has been sub-
stantiated in a recent integrated genom-
ics approach that has identified MITF as 
a lineage survival oncogene amplified in 
melanoma (Garraway et al., 2005). With 
increasing resolution of array CGH plat-cancer cell : december 2005 forms for mapping chromosomal altera-
tions and advances in expression and 
sequencing technologies, it is anticipated 
that the discovery of novel melanoma rel-
evant genes will accelerate dramatically 
in the near future.
High-resolution charting of recurrent 
copy number aberrations by array CGH 
will also provide the basis for molecular 
classification that, when combined with 
clinical information, will define genotype-
phenotype correlation and biomarkers that 
can enhance existing staging systems for 
patient stratification. For example, correlat-
ing melanomas arising in different anatomi-
cal sites with different UV exposure patterns 
to distinct genomic signatures should lead 
to an understanding of the genetic modula-
tors and targets of UV’s mutagenic actions 
in this cancer. In the November 17 issue 
of The New England Journal of Medicine, 
Curtin et al. (2005) took an important first 
step in defining such gene-environment 
interactions in melanoma.
In this study, Curtin and colleagues 
conducted a genome-wide analysis of 
DNA copy number and mutational analy-
sis of BRAF and NRAS in 126 melanomas 
from individuals with varying UV exposure 
histories (Curtin et al., 2005). Distinctive 
patterns of genomic alterations as well as 
differences in frequencies of BRAF and 
NRAS mutations were observed among 
the four groups of melanomas examined. 
Genomic instability was most prominent 
in melanomas arising on skin protected 
from direct UV light. Specifically, acral 
melanomas of the palms and soles and 
mucosal melanomas exhibited high num-
bers of whole-genome gains and losses, 
intrachromosomal copy number changes, and focal amplifications (Figure 1). On the 
other hand, amplifications and deletions 
were infrequent in melanomas arising on 
skin with chronic sun-induced damage (as 
defined by evidence of solar elastosis on 
histology) and those from skin with inter-
mittent UV exposure but without chronic 
damage (Figure 1). There were differences 
not only in the levels of genomic instability 
for the four melanoma subgroups, but also 
in their patterns of chromosomal gains 
and losses (Figure 1). Genomic clas-
sification was able to classify acral and 
mucosal melanomas with 89% accuracy. It 
was also possible to distinguish between 
melanomas from skin exhibiting signs of 
chronic sun-induced damage and those 
from skin without signs of damage with 
84% accuracy. That genomic signatures 
capable of classifying melanoma from dif-
ferent anatomic sites can be defined is a 
definitive proof that melanoma is a geneti-
cally heterogeneous disease.
In addition to their genomic patterns, 
the mutational spectrum was different 
between melanomas from sun-exposed 
and sun-protected skin (Figure 1). In par-
ticular, this study extended the group’s 
earlier findings that melanomas from 
chronically sun-exposed and non-sun-
exposed skin differed significantly in the 
mutation frequency of BRAF (Maldonado 
et al., 2003). In all melanoma groups, 
BRAF and NRAS mutations were found 
to be mutually exclusive. The presence of 
activating BRAF mutations inversely cor-
related with copy number gains of CCND1, 
and both events were associated with 
higher levels of CCND1 protein expression. 
Amplification of CDK4, encoding a CCND1 
binding partner, was commonly seen in 439
	 p r e v i e w sFigure 1. summary of genetic alterations 
in melanomas from patients with varying 
degrees of sun exposure as reported by curtin 
et al.
melanomas from skin with evidence of chronic 
sun damage, intermittent sun exposure with-
out evidence of damage, and no significant 
exposure exhibit distinct genomic patterns of 
gain/amplification and loss/deletion and dif-
ferent BRAF/NRAS mutational spectrums. BRAF 
and NRAS mutations were mutually exclusive, 
as were BRAF/NRAS activating mutations and 
increased copies of CCND1 or CDK4. gain/
amplification of CDK4 was more commonly 
seen in melanomas from protected skin than 
in melanoma from sun-exposed skin, as was 
deletion/loss of the CDNK2A locus, which was 
observed exclusively in samples without CDK4 
amplification. UV, ultraviolet light; Wt, wild-
type; mt, mutant; amp, amplification.acral and mucosal melanomas but not 
observed in tumors with activating BRAF 
or NRAS mutations or CCND1 copy num-
ber gains. Furthermore, losses/deletions 
of the melanoma suppressor CDKN2A 
locus, whose protein product antagonizes 
CCND1-CDK4 interaction, were also more 
commonly detected in mucosal and acral 
melanomas, but only in samples without 
CDK4 amplification. Activation of the PI3K 
pathway was evidenced by increased levels 
of phosphorylated AKT protein in melano-
mas with concurrent BRAF mutations and 
chromosome 10 losses that encompassed 
the PTEN tumor suppressor, as well as in 
specimens with NRAS mutations alone, 
which is in line with the previous finding 
that NRAS mutations could result in dual 
activation of the MAPK and PI3K pathways 
(Tsao et al., 2000; Curtin et al., 2005).
While the differences between mela-
noma from sun-protected skin (acral and 
mucosal sites) cannot be attributed to UV, 
the distinct genomic profiles between mel-
anomas arisen on chronically versus inter-
mittently sun-exposed sites may provide 
new insights in defining complex gene-
environment interactions that underlie dis-
ease pathogenesis. For instance, the study 
reports that melanomas from sun-dam-
aged skin are typically wild-type for BRAF 
and often arise in conjunction with solar 
keratoses and other UV-related lesions 
in older individuals with high cumulative 
UV dose. In comparison, melanomas from 
skin intermittently exposed to UV harbor 
a high frequency of BRAF mutations and 
are often diagnosed in younger individuals 
who have larger numbers of moles. These 
contrasting characteristics have suggested 440 to the authors that a potential difference in 
genetic susceptibility to UV exposure and 
melanoma exists in certain Caucasian 
populations (Curtin et al., 2005).
The recognition of the genomic het-
erogeneity of different types of melanoma 
has important clinical and therapeutic 
implications, as it has a direct impact on 
design and development of prevention 
and therapeutic approaches. For example, 
since activation of MAPK (BRAF/NRAS) 
and the PI3K pathways are important in 
the subgroup of melanoma from skin with 
intermittent UV exposure, which is the 
most common form of the disease, BRAF 
may provide a logical target for therapeu-
tic intervention (reviewed in Tuveson et al., 
2003). Conversely, in the case of melano-
mas from chronically sun-damaged skin 
or from UV-protected sites, which typically 
do not acquire BRAF mutations but rather 
amass higher copy numbers of CCND1 
or CDK4, a therapeutic approach involv-
ing CDK inhibitors might yield a positive 
response (Curtin et al., 2005). In addition, 
the definition of subtype-specific genomic 
and genetic signatures will serve as the 
entry point for discovery of novel mela-
noma genes that may serve as future 
therapeutic targets and may assist in the 
construction of refined preclinical mod-
els. As reported in this study, gain/ampli-
fication and loss/deletion appeared to 
encompass large chromosomal regions. 
Therefore, much work remains, including 
the examination of melanomas of similar 
and distinct etiologies and their metastatic 
counterparts utilizing high-resolution oli-
gonucleotide or tiling BAC array platforms 
to identify a limited number of copy num-ber-altered genes that can be enlisted into 
a functional validation pipeline.
Accurate diagnosis, prognosis, strati-
fication, and management of melanoma 
patients will likely require integration of a 
multitude of biomarkers on epidemiologi-
cal (e.g., UV exposure history), predispo-
sition genetic (e.g., MC1R polymorphism 
or CDKN2A mutation), clinical (e.g., age, 
gender, or site), and histopathological (e.g., 
Breslow thickness, tumor-infiltrating lym-
phocytes) levels in addition to the molecu-
lar signatures. On this note, it is clear that 
chromosomal alterations and mutational 
analysis of key melanoma genes do not 
present a complete molecular view of the 
melanoma genome. Epigenetic modifica-
tions, transcriptome profiles of both cod-
ing and noncoding RNAs, and the tumor 
and/or serum proteomes will be required 
to generate a more comprehensive pic-
ture of the factors driving melanoma and 
other cancers in general. What Curtin and 
colleagues reported in this study repre-
sents a proof-of-principle illustration of 
the importance and power of systematic 
genome-wide characterization of clinically 
annotated tumor specimens.
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